{"entity":{"id":"nct05767892","kind":"trial","name":"YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations","aka":[],"tldr":"A phase 3 trial of pemetrexed, carboplatin and cisplatin in lung cancer, run by Suzhou Puhe Pharmaceutical Technology Co., LTD, not yet recruiting.","summary":"YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations is a phase 3, randomised interventional study registered as NCT05767892 by Suzhou Puhe Pharmaceutical Technology Co., LTD, with a registry enrolment figure of 350 participants, started 2023-05-01 and due to reach its primary completion in 2025-07-30. Interventions recorded: YK-209A tablet; Pemetrexed+carboplatin/Cisplatin. Conditions listed: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC). Primary outcome: Progression Free Survival (PFS) as Assessed by Blinded Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 .. Lung eligibility wording from the registry: \"Histologically or cytologically confirmed nonsquamous cell locally advanced not suitable for definitive therapy, recurrent, or metastatic (Stage IV) NSCLC\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT05767892","url":"https://clinicaltrials.gov/study/NCT05767892"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["egfr-mutant-nsclc"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["pemetrexed","carboplatin","cisplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05767892","phase":"3","setting":"A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations","sponsor":"Suzhou Puhe Pharmaceutical Technology Co., LTD","enrolled":350,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05767892/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}